KalVista Pharmaceuticals (KALV) Competitors $8.36 +0.27 (+3.34%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KALV vs. XNCR, EVO, ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, MESO, and NTLAShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Xencor Evotec Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Intellia Therapeutics Xencor (NASDAQ:XNCR) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership. Does the MarketBeat Community favor XNCR or KALV? Xencor received 165 more outperform votes than KalVista Pharmaceuticals when rated by MarketBeat users. However, 74.62% of users gave KalVista Pharmaceuticals an outperform vote while only 73.44% of users gave Xencor an outperform vote. CompanyUnderperformOutperformXencorOutperform Votes50673.44% Underperform Votes18326.56% KalVista PharmaceuticalsOutperform Votes34174.62% Underperform Votes11625.38% Is XNCR or KALV more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xencor-232.77% -30.92% -21.74% KalVista Pharmaceuticals N/A -103.92%-88.06% Which has better earnings and valuation, XNCR or KALV? Xencor has higher revenue and earnings than KalVista Pharmaceuticals. Xencor is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$85.16M19.83-$126.09M-$3.20-7.54KalVista PharmaceuticalsN/AN/A-$126.64M-$3.64-2.30 Which has more volatility and risk, XNCR or KALV? Xencor has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Do analysts recommend XNCR or KALV? Xencor presently has a consensus price target of $36.56, suggesting a potential upside of 51.49%. KalVista Pharmaceuticals has a consensus price target of $23.33, suggesting a potential upside of 179.11%. Given KalVista Pharmaceuticals' higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Xencor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to XNCR or KALV? In the previous week, KalVista Pharmaceuticals had 5 more articles in the media than Xencor. MarketBeat recorded 10 mentions for KalVista Pharmaceuticals and 5 mentions for Xencor. Xencor's average media sentiment score of 0.89 beat KalVista Pharmaceuticals' score of 0.33 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryXencor beats KalVista Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$413.13M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-2.3010.5989.9717.18Price / SalesN/A195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book3.085.094.784.78Net Income-$126.64M$151.83M$120.23M$225.60M7 Day Performance-3.80%-2.13%-1.92%-1.23%1 Month Performance-9.87%-3.10%11.49%3.36%1 Year Performance-25.82%11.54%30.57%16.60% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.9529 of 5 stars$8.36+3.3%$23.33+179.1%-24.0%$413.13MN/A-2.30150Analyst ForecastHigh Trading VolumeXNCRXencor4.3204 of 5 stars$24.84+3.4%$36.56+47.2%+18.4%$1.74B$168.34M-7.51280EVOEvotec2.387 of 5 stars$4.69+4.5%$5.93+26.5%-60.5%$1.66B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.8599 of 5 stars$13.34+5.1%$15.50+16.2%+478.8%$1.56B$138.71M-7.58150Options VolumePositive NewsNRIXNurix Therapeutics2.5066 of 5 stars$21.19+4.5%$30.35+43.2%+101.7%$1.50B$56.42M-6.97300News CoverageRCUSArcus Biosciences2.6476 of 5 stars$16.25+1.1%$34.00+109.2%-9.3%$1.49B$117M-5.11500News CoverageKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.40+1.0%$36.60+79.4%+15.4%$1.47B$384.10M-147.36220Positive NewsIMCRImmunocore2.4974 of 5 stars$29.05+0.5%$65.64+125.9%-51.4%$1.45B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.6452 of 5 stars$8.98+3.3%$16.71+86.1%+116.8%$1.41B$58.44M0.00267Positive NewsMESOMesoblast1.0377 of 5 stars$12.18+3.6%$11.50-5.6%+590.1%$1.39B$5.90M0.0080Analyst ForecastOptions VolumeNews CoveragePositive NewsNTLAIntellia Therapeutics4.2166 of 5 stars$13.50+4.7%$54.94+306.9%-58.9%$1.37B$36.28M-2.37600 Related Companies and Tools Related Companies XNCR Alternatives EVO Alternatives ARQT Alternatives NRIX Alternatives RCUS Alternatives KNSA Alternatives IMCR Alternatives OCUL Alternatives MESO Alternatives NTLA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KALV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
